Loading...

UFP Technologies, Inc.

UFPTNASDAQ
Healthcare
Medical - Devices
$220.94
$-4.80(-2.13%)

UFP Technologies, Inc. (UFPT) Financial Performance & Income Statement Overview

Explore the financials of UFP Technologies, Inc. (UFPT), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
26.08%
26.08%
Operating Income Growth
40.29%
40.29%
Net Income Growth
31.29%
31.29%
Operating Cash Flow Growth
61.11%
61.11%
Operating Margin
16.05%
16.05%
Gross Margin
28.76%
28.76%
Net Profit Margin
11.40%
11.40%
ROE
18.93%
18.93%
ROIC
21.07%
21.07%

UFP Technologies, Inc. (UFPT) Income Statement & Financial Overview

Explore comprehensive income reports for UFP Technologies, Inc. UFPT, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$148.15M$144.07M$145.16M$110.18M
Cost of Revenue$106.00M$102.01M$103.64M$77.15M
Gross Profit$42.15M$42.06M$41.52M$33.03M
Gross Profit Ratio$0.28$0.29$0.29$0.30
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$18.73M$18.62M$15.79M$13.90M
Operating Expenses$18.73M$19.80M$15.79M$13.90M
Total Costs & Expenses$124.72M$120.63M$119.43M$91.05M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$2.81M$3.38M$3.48M$577000.00
Depreciation & Amortization$0.00$4.66M$4.03M$3.03M
EBITDA$23.13M$27.13M$28.72M$22.16M
EBITDA Ratio$0.16$0.19$0.20$0.20
Operating Income$23.13M$22.26M$24.76M$19.13M
Operating Income Ratio$0.16$0.15$0.17$0.17
Other Income/Expenses (Net)-$2.85M-$3.16M-$3.54M-$579000.00
Income Before Tax$20.28M$19.10M$21.22M$17.37M
Income Before Tax Ratio$0.14$0.13$0.15$0.16
Income Tax Expense$3.10M$2.72M$4.86M$3.82M
Net Income$17.18M$16.38M$16.36M$13.55M
Net Income Ratio$0.12$0.11$0.11$0.12
EPS$2.24$2.14$2.13$1.77
Diluted EPS$2.21$2.10$2.11$1.75
Weighted Avg Shares Outstanding$7.69M$7.67M$7.67M$7.67M
Weighted Avg Shares Outstanding (Diluted)$7.78M$7.79M$7.77M$7.75M

Over the past four quarters, UFP Technologies, Inc. demonstrated steady revenue growth, increasing from $110.18M in Q2 2024 to $148.15M in Q1 2025. Operating income reached $23.13M in Q1 2025, maintaining a consistent 16% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $23.13M, reflecting operational efficiency. Net income rose to $17.18M, with EPS at $2.24. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;